SWOG clinical trial number
SWOG-9205

Central Prostate Cancer Serum Repository Protocol

Closed
Phase
Abbreviated Title
Ancillary Prostate
Activated
10/01/1992
Closed
10/01/2006
Participants
NCORP, Members, UCOP, Medical Oncologists, Surgeons, Pathologists, Affiliates

Research committees

Genitourinary Cancer

Eligibility Criteria Expand/Collapse

Pt must be eligible for and registered to a SWOG protocol for carcinoma of the prostate. Pts must submit greater than/equal to 3 ml of unthawed serum from baseline.

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase